Samir Parekh, MBBS

Clinical Focus

• Lymphoma
• Multiple Myeloma

• Lymphoma
• Multiple Myeloma

Research

Locations

Ruttenberg Treatment Center

1470 Madison Avenue, 3rd Floor, New York, NY, 10029

212-241-7873

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:30

Article:73

Review Article:13

Comment/Debate:4

Letter:9

Editorial:3

Chapter:1

Recent Artifacts

• Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
• Erratum: Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements (Communications biology (2022) 5 1 (1295))
• Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
• A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements
• Dupilumab in Multiple Myeloma: A Case Series
• Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
• High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments
• MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy
• CD8⁺ T cells: An ineffective armor against prolonged COVID-19 in cancer patients
• A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Parekh during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.